Work

P110 Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors

Year: 2024

Type: conference-abstract

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae360.140

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405230243

Cites:

Cited by:

Related to: 10